Covestor’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,745
| Closed | -$25K | – | 2600 |
|
|
2026
Q1 | $25K | Sell |
1,745
-5,403
| -76% | -$77.5K | 0.02% | 1018 |
|
|
2025
Q4 | $102K | Sell |
7,148
-6,079
| -46% | -$59.7K | 0.05% | 566 |
|
|
2025
Q3 | $104K | Buy |
13,227
+3,846
| +41% | +$27.4K | 0.06% | 560 |
|
|
2025
Q2 | $54K | Buy |
9,381
+3,363
| +56% | +$21.7K | 0.03% | 866 |
|
|
2025
Q1 | $49K | Buy |
6,018
+1,693
| +39% | +$15.7K | 0.03% | 851 |
|
|
2024
Q4 | $41K | Buy |
4,325
+2,312
| +115% | +$24K | 0.03% | 926 |
|
|
2024
Q3 | $22K | Buy |
2,013
+1
| +0% | +$11 | 0.01% | 1176 |
|
|
2024
Q2 | $20K | Sell |
2,012
-1,526
| -43% | -$15.7K | 0.01% | 1199 |
|
|
2024
Q1 | $42K | Buy |
3,538
+881
| +33% | +$11.3K | 0.03% | 948 |
|
|
2023
Q4 | $38K | Buy |
2,657
+1,686
| +174% | +$19.1K | 0.03% | 964 |
|
|
2023
Q3 | $12K | Buy |
971
+624
| +180% | +$8.05K | 0.01% | 1324 |
|
|
2023
Q2 | $4K | Sell |
347
-1,776
| -84% | -$21.1K | ﹤0.01% | 1722 |
|
|
2023
Q1 | $24K | Buy |
2,123
+2,101
| +9,550% | +$25.9K | 0.02% | 939 |
|
|
2022
Q4 | $0 | Sell |
22
-2,022
| -99% | -$22.8K | ﹤0.01% | 2232 |
|
|
2022
Q3 | $21K | Buy |
2,044
+2,008
| +5,578% | +$22.4K | 0.02% | 977 |
|
|
2022
Q2 | $0 | Sell |
36
-10
| -22% | -$82 | ﹤0.01% | 2071 |
|
|
2022
Q1 | $0 | Sell |
46
-11
| -19% | -$103 | ﹤0.01% | 2220 |
|
|
2021
Q4 | $1K | Buy |
+57
| New | +$635 | ﹤0.01% | 1749 |
|
Other funds holding FOLD
Covestor's FOLD Position: Q2 2026 in Review
Covestor sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 1,745 shares — an estimated $25K sold.
Covestor first reported a position in FOLD in Q4 2021 and held it in 18 quarters. The position peaked at $104K in Q3 2025. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Covestor reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Covestor sold 1,745 Amicus Therapeutics shares in Q2 2026, an estimated $25K.
- Covestor first reported a position in Amicus Therapeutics in Q4 2021 and held it in 18 quarters.
- Covestor's Amicus Therapeutics position peaked at $104K in Q3 2025.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.